MindMed appoints Schond Greenway as CFO, effective May 23, 2022

Definium Therapeutics, Inc.

Schond Greenway named CFO effective May 23, 2022; previously CFO at Avalo Therapeutics.
Base salary of $400,000; eligible for discretionary annual cash bonus with 40% target.
Received option for 1,650,000 shares (4-yr vest) and RSU for 1,270,000 shares (4-yr vest).
Greenway brings experience from Avalo, Mesoblast, Halozyme, and investment banks.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Schond Greenway

Chief Financial Officer

DFTX · Definium Therapeutics, Inc.

Effective: 2022-05-23
Filed: May 23, 2022, 7:59 PM ET

On May 23, 2022, Mind Medicine (MindMed) Inc. (the “Company”) announced the appointment of Schond Greenway as the Company’s Chief Financial Officer, effective May 23, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Schond Greenway was appointed as Chief Financial Officer at Definium Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 23, 2022, Mind Medicine (MindMed) Inc. (the “Company”) announced the appointment of Schond Greenway as the Company’s Chief Financial Officer, effective May 23, 2022

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-157512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.